

Evonik makes its debut at Tokyo Agri Week

13 October 2021

- System solutions for efficient and sustainable livestock farming
- Focus on the entire value chain of animal protein production
- Focus on gut health of broilers, layers and swine

Main press contact

Yama Olumi
Head of Market Communications
Animal Nutrition
Phone + 49 6181 59-12437
yama.olumi@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications
Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Essen, Germany. For the first time, Evonik will have its own booth at the Tokyo Livestock Show, part of Tokyo Agri Week from October 13 to 15, where it will present system solutions for sustainable livestock farming. Evonik aims to meet farmers, consultants, integrators, and veterinarians at the show.

"To meet today's challenges in agricultural animal husbandry, several adjusting screws must be turned simultaneously: animal health, animal nutrition and farm management," says Mitsuru Hori, Business Director Japan & South Korea for the Animal Nutrition business line of Evonik.

Starting with feed additives such as amino acids, Evonik has therefore greatly expanded its range of products for the livestock industry in recent years, in order to contribute to efficient, sustainable, and high-quality production of meat, eggs, and dairy products at various points along the value chain.

Take Gut Health Solutions, for example: "Gut health is a key factor when it comes to keeping animals healthy without the use of antibiotics and at the same time operating sustainably and profitably," says Hori. "Performance can only be successfully stabilized with holistic approaches."

Evonik's knowledge-based system solutions for the gut health of broilers, layers and swine include a tailored combination of feeding concepts, amino acids, probiotics, services and advice, depending on the individual needs and challenges of the customers.

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Evonik will present all these components at the Tokyo Livestock Show: from MetAMINO® to GuanAMINO®, from GutCare® to GutPlus®, from AMINODat® 6.0 to AMINONIR® Portable – and last but not least Porphyrio®, a tool for precision livestock farming in the poultry sector.

For dairy farming, Evonik's product range includes the rumen-protected methionine derivative Mepron® and AMINOCow® for determining the optimal feed composition. In addition, the topic of sustainability will occupy a large space at the Evonik booth No. 6–52.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.